pentetic acid has been researched along with quinazolines in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brechbiel, MW; Burgess, AW; Hall, C; Johns, TG; Kelly, MP; Lee, FT; Mountain, AJ; Nice, EC; Rigopoulos, A; Scott, AM; Smyth, FE | 1 |
| Bailey, KE; Cai, Z; Chen, Z; Costantini, DL; Reilly, RM; Scollard, DA; Vallis, KA | 1 |
| Brechbiel, MW; Davis, ID; Kelly, MP; Lee, FT; Lee, ST; Scott, AM; Smyth, FE | 1 |
3 other study(ies) available for pentetic acid and quinazolines
| Article | Year |
|---|---|
Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Lewis Blood Group Antigens; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pentetic Acid; Protein-Tyrosine Kinases; Quinazolines; Radioimmunotherapy; Radiopharmaceuticals; Signal Transduction; Time Factors; Tissue Distribution; Tyrphostins; Yttrium Radioisotopes | 2005 |
Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
Topics: Antineoplastic Agents; Cell Compartmentation; Cell Line, Tumor; Cell Nucleus; Electrons; Epidermal Growth Factor; ErbB Receptors; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Gefitinib; Humans; Indium Radioisotopes; Pentetic Acid; Phosphorylation; Protein Transport; Quinazolines; Radiopharmaceuticals; Signal Transduction | 2007 |
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Radiation; Enzyme Inhibitors; ErbB Receptors; Humans; Isothiocyanates; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pentetic Acid; Phosphorylation; Prostatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radioimmunotherapy; Radioisotopes; Taxoids; Tyrphostins; Xenograft Model Antitumor Assays | 2009 |